Current Opinion in Oncology was launched in 1989. It is one of a successful series of review journals whose unique format is designed to provide a systematic and critical assessment of the literature as presented in the many primary journals. The field of psychiatry is divided into 15 sections that are reviewed once a year. Each section is assigned a Section Editor, a leading authority in the area, who identifies the most important topics at that time. Here we are pleased to introduce the Journal's Section Editors for this issue.
Joël Guigay is Professor of Medicine and Past Director of Cancer Center Antoine-Lacassagne in Nice, France, from 2014 to 2019. Prior to this, he was Head Physician in the Department of Head & Neck and Thoracic Medical Oncology at Gustave Roussy in Villejuif, France. Professor Guigay received his Medical Degree from Lyon University of Medicine in 1984 and subsequently undertook extensive postgraduate training in Pneumology, Cancerology, Oncogenesis, and Thoracic Endoscopy. In 2001, he was appointed Professor of Medicine at the Hôpital d’Instruction des Armées Val-de-Grâce in Paris, France.
He currently serves as the president of the Head and Neck-Unicancer group, and as deputy director of the Hospital University Federative OncoAge. In addition, he is an active member of many national and international societies, including the American Society of Clinical Oncology (ASCO), the European Society for Medical Oncology (ESMO) as a Faculty member for Head and Neck cancers and as a member of the OncologyPro WG, the International Association for the Study of Lung Cancer (IASLC), the Groupe Oncologie Radiothérapie Tête et Cou (GORTEC) as a member of the board and the scientific committee, and the Intergroupe Francophone de Cancérologie Thoracique (IFCT).
His main fields of interest are head and neck and lung oncology with a focus on rare tumors, salivary gland tumors, nasopharyngeal cancers and neuroendocrine tumors. His areas of research include clinical studies with new drugs and translational research with a focus on immunotherapy. Professor Guigay coordinates several clinical trials including phase I to large randomized trials in recurrent or metastatic HNSCC such as TPExtreme trial. He currently also leads a large research program for elderly head and neck cancer patients (ELAN study).
He has published more than 150 articles, reviews or book chapters.
Arif Hussain, MD, is Professor of Medicine with Tenure in the Department of Medicine, School of Medicine, at the University of Maryland in Baltimore, USA, where he is also Professor of Biochemistry in the Department of Biological Chemistry and Professor of Pathology in the Department of Pathology. He also serves as Co-Leader of the Hormone Responsive Cancers Program in the Greenebaum Cancer Center, University of Maryland. Dr Hussain's clinical interest is in genitourinary cancers, and he serves as Principal Investigator on several clinical trials that focus on therapies for high risk, recurrent and metastatic prostate cancer, as well as renal cell cancer. In addition, he has a research laboratory focusing on drug resistance, intracellular calcium pumps, and pre-clinical models of prostate cancer.
Christiane Jungels, MD, is a Medical Oncologist at the Jules Bordet Institute in Brussels, Belgium. A Luxembourgish citizen, she came to Belgium in 2004 for Medical School at the Université Libre de Bruxelles (ULB), where she graduated as a Medical Doctor in 2010. She first trained in internal medicine, and later did her training in medical oncology at the Jules Bordet Institute, and graduated as a medical oncologist in 2016. She has been working in the Institute as a specialist since the end of 2016, with a primary interest in the management of rare tumors, including sarcomas and endocrine tumors. Besides coordinating projects focusing on rare tumors, her main activity is clinical research, especially early drug development for patients with solid tumors with a special commitment to rare tumors. She is local Principal Investigator for several phase 1 trials and co-investigator in many phase 1 to 3 studies.
She is member of the Belgian Society for Medical Oncology (BSMO) and the European Society for Medical Oncology (ESMO).